

Scientific Program Meeting 2008 Day 1 (15th May 2008)

8:30-8:35 **Welcoming Address**

C. Huber (Mainz)

Session 1: Antigen-Processing

Chairperson: *H.G. Rammensee (Tübingen), C. Huber (Mainz)*

08:35-09:10 The puzzles in peptide selection by class II histocompatibility molecules
E. Unanue (St. Louis) – Keynote

09:10-09:45 Spatial separation of cross-presentation and endogenous antigen presentation
S. Burgdorf (Bonn)

09:45-10:40 Genome-wide analysis of factors controlling MHC class II antigen presentation: roles of cholesterol and motor proteins
J. Neefjes (Amsterdam)

10:40-10:50 **Coffee Break**

Session 2: Cellular Therapy

Chairperson: *W. Herr (Mainz), M. Gramatzki (Kiel)*

10:50-11:25 Memory makers - establishing persistent immunity by adoptive T cell transfer
S. Riddell (Seattle)

11:25-12:00 Dissecting T cell responses with self-destructive MHCs and barcodes
T. Schumacher (Amsterdam)

12:00-12:35 Improving reactivity and safety of T cell receptor gene-modified T cells
W. Uckert (Berlin)

12:35-13:30 **Lunch Break**

Poster Session I

13:00-14:15 **Guided Poster Session**

Session 3: Breaking the Immune Barriers

Chairperson: T. Wölfel (Mainz), H. Schild (Mainz)

- 14:15-14:50 Inflammation and Immune Regulation in the Development of Colon Cancer
C. Becker (Mainz)
- 14:50-15:25 Immune activation and regulation at the cutaneous site of vaccination
C. Slingluff Jr. (Charlottesville)
- 15:25-16:00 Dendritic cell homeostasis regulates T cell awareness of antigen
N. Garbi (Heidelberg)
- 16:00-16:30 **Coffee Break**



Parallel events

Short talk presentations

Short talk presentation: Therapeutic Vaccination

Chairperson: S. Grabbe (Mainz), J. Weber (Tampa)

- 16:30-16:45 **P45:** DNA fusion gene vaccination, delivered with or without in vivo electroporation - a potent and safe strategy for inducing anti-tumor immune responses in prostate cancer
Lindsey Low (Southampton)
- 16:45-17:00 **P10:** Immunological and clinical outcome of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) vaccinated with 300 or 1000 mcg RHAMM-R3 peptide
Michael Schmitt (Ulm)
- 17:00-17:15 **P49:** Dynamics of tumor-specific immune responses in patients affected by metastatic melanoma following vaccination with autologous lymphocytes genetically modified to express the MAGE-3 tumor antigen
Raffaella Fontana (Milan)
- 17:15-17:30 **P75:** HLA ligands in lung cancer
A. Neumann (Tübingen)
- 17:30-17:45 **P98:** Comparison of immune responses after vaccination with tumor-peptide-loaded dendritic cells with or without prior denileukin diftitox treatment in metastasized malignant melanoma
Michael Erdmann (Erlangen)
- 17:45-18:00 **P08:** Immune response induced by therapeutic vaccination with epidermal growth factor (EGF) in NSCLC patients
Z. Mazorra (Havana)



Short talk presentation: Enhancing Immunity and Adjuvants

Chairperson: P. Brossart (Bonn), K. Thielemans (Brussels)

- 16:30-16:45 **P83:** A phase I clinical trial with TriMix-Dendritic cell vaccine in advanced melanoma patients, preliminary results
Kris Thielemans (Brussels)
- 16:45-17:00 **P22:** Recombinant tumor vaccines targeted to CD40 for selective uptake by professional antigen presenting cells
Ute Burkhardt (Frankfurt)
- 17:00-17:15 **P102:**
Sebastian Kreiter (Mainz)
- 17:15-17:30 **P56:** Preclinical evaluation of novel immunotherapeutic strategies: Adjuvant administration of TLR-agonists enhances the therapeutic efficacy of adoptively transferred T cells against primary cutaneous melanoma in HGF x Cdk4R24C mice
Judith Kohlmeyer (Bonn)
- 17:30-17:45 **P28:** Combining radio- and immunotherapy: The La protein on irradiated tumor cells as surface target molecule for a universal immunotherapy
Claudia Franke (Dresden)
- 17:45-18:00 **P15:** Phenotypic and functional properties of regulatory T cells in a mouse model of spontaneous melanoma
Silvia Kimpfler (Heidelberg)
-

Short talk presentation: Cellular Therapy

Chairperson: G. Pawelec (Tübingen), W. Uckert (Berlin)

- 16:30-16:45 **P37:** Activated $\gamma\delta$ T cells- an alternative for antigen specific immunotherapy?
Silke Landmeier (Münster)
- 16:45-17:00 **P99:** Evaluation of engraftment and graft-vs-host reactivity of ex vivo modified human donor T cell grafts in a chimeric NOD/SCID/IL2R γ ^{null} transplantation model
Marion Nonn (Mainz)
- 17:00-17:15 **P88:** Induction of MAGE-specific donor T-cells for active immunotherapy in multiple myeloma
Ines Möller (Freiburg)
- 17:15-17:30 **P95:** Detection and enrichment of antigen-specific naïve and effector/memory CD4⁺ and CD8⁺ T cells according to CD137 and CD154 expression
Sonja Schmucker (Tübingen)
- 17:30-17:45 **P61:** Reprogramming of bulk T cells with a tumor-antigen specificity by electroporation of RNA encoding chimeric T cell receptors
Niels Schaft (Erlangen)
- 17:45-18:00 **P108:** Functionality of a human gp100 specific single chain TCR can be achieved by its partial murinisation
Beate Hauptrock (Mainz)
-

19:15-23:30 **Social Event:** Dinner on a Rhine river cruise

Scientific Program Meeting 2008

Day 2 (16th May 2008)

Session 4: Therapeutic Vaccination

Chairperson: G. Parmiani (Milan), G. Schuler (Erlangen)

09:00-09:35 Clinical and pre-clinical use of immunoregulatory antibodies in melanoma
J. Weber (Tampa)

09:35-10:10 Cancer immunotherapy - new directions for development
A. Hoos (BMS, Wallingford)

10:10-10:25 **Coffee Break**

Session 4 (cont.): Therapeutic Vaccination

10:25-11:00 From targets to cancer immunotherapies
U. Sahin (Mainz)

11:00-11:35 Dendritic cells as vectors and targets for cancer therapy
A. K. Palucka (Dallas)

Parallel events

Poster Session II

11:40-12:40 **Guided Poster Session**

Workshop: MHC Multimer Flow Cytometry

- with finger-food for participants instead of regular lunch –

Workshop organized in association with Beckman Coulter.

11:40-12:40 Life/Dead discrimination and dump channel in MHC Multimer Flow Cytometry
Matthias Schiemann (Munich) - oral presentation and live analysis

12:30-12:50 Identification of new T cell epitope candidates using the iTOPIATM EDS
Felix Montero (Beckman Coulter) - oral presentation

12:50-13:40 Cytometry based functional analysis of tetramer-positive T cell subpopulations
Eckhart Kämpgen (Erlangen) - oral presentation and live cell analysis

12:30-13:45 **Lunch Break**

Session 5: New Strategies

Chairperson: *T. Hinz (Langen), U. Sahin (Mainz)*

13:45-14:20 Antigen cross presentation by dendritic cells
S. Amigorena (Paris)

14:20-14:55 Manipulating regulatory T cells to augment therapeutic anti-cancer immunity in mice and humans
B. Fox (Portland)

14:55-15:30 Exploring the fine specificity of CD4+foxP3+ regulatory T cell mediated suppression of anti-tumor immunity
H. Levitsky (Baltimore)

15:30-15:45 **Coffee Break**

Session 6: Immunomonitoring – organized by CIMT Monitoring Panel

Chairperson: *C. Britten (Leiden), C. Gouttefangeas (Tübingen)*

15:45-15:55 Introduction
(chairs)

15:55-16:25 Multifunctional assessment of T cells: Correlate of vaccine protection
M. Roederer (Bethesda)

16:25-16:55 Acceptance criteria for thawed cell samples used for T cell immuno monitoring
J. Smith (West Point)

16:55-17:25 Immunomonitoring in clinical trials – How many different assays do we really need?
S. van der Burg (Leiden)

17:25-17:35 Update on the CIMT Immunomonitoring panel III/2007 Tetramer
C. Gouttefangeas (Tübingen)

17:35-17:45 Update on the CIMT Immunomonitoring panel IV/2007 ELISPOT
A. Mander (Southampton)

17:45-17:55 Update on the CIMT Immunomonitoring panel V/2007 ICS
M. Welters (Leiden)

17:55-18:10 The CVC proficiency panel program
S. Janetzki (New York)

18:10-18:20 Final discussion
All participants



Guided Poster Sessions

Session I **Thursday, 15.05.2008** **13:00 – 14:15 hrs**

Session II **Friday, 16.05.2008** **11:40 – 12:40 hrs**

Session title	Session	Abstract number	Chair
Therapeutic vaccination	Session I	P06, P08, P10, P16, P22, P31, P45, P46, P49, P51	C. Ottensmeier (Southampton)
	Session II	P60, P66, P77, P78, P83, P100, P102, P110, P111	P. Walden (Berlin)
Immune monitoring	Session I	P05, P35, P36, P41, P43, P44, P79	E. Kämpgen (Erlangen)
	Session II	P80, P81, P84, P85, P90, P95, P98	S. van der Burg (Leiden)
Antibodies in tumor therapy	Session I	P24, P26, P27, P28, P29, P33, P39	Ö. Türeci (Mainz)
	Session II	P52, P57, P58, P59, P63, P106	W. Wels (Frankfurt)
Cellular therapy	Session I	P34, P37, P40, P61, P62, P64, P71	W. Herr (Mainz)
	Session II	P72, P88, P93, P99, P105, P108	R. G. Meyer (Mainz)
New targets	Session I	P02, P09, P11, P13, P17, P18, P21, P23, P112	M. Schmitt (Ulm)
	Session II	P32, P50, P75, P87, P91, P97, P104, P109, P114	S. Stevanovic (Tübingen)
Tumor biology / interaction with immune system	Session I	P07, P14, P15, P25, P42, P54, P55, P65	A. Letsch (Berlin)
	Session II	P68, P69, P70, P73, P94, P96, P107, P113	V. Umansky (Heidelberg)
Enhancing immunity and adjuvants	Session I	P03, P04, P12, P19, P30, P38, P47, P48, P53	T. Wölfel (Mainz)
	Session II	P56, P67, P74, P76, P82, P86, P89, P92, P103	M. Radsak (Mainz)